AQ Biotech raises €2.5M seed to scale urine cancer test in China
What's the deal? Turku-based diagnostic startup AQ Biotech (Aqsens Health)Dealroom has a profile for this one. Try Dealroom → has closed €2.5 million in seed funding, the company said, to commercialise an antibody-free test that detects cancer from urine samples. The round mixes equity from undisclosed private investors with research-and-development support from Business FinlandDealroom has a profile for this one. Try Dealroom →. Chief executive officer and co-founder Timo Teimonen declined to name the private backers or disclose the valuation.
Why now? The capital funds a geographic push into Hong Kong and mainland China, plus hiring in both regions. China offers patient populations large enough to generate the clinical evidence diagnostics firms need to win over regulators and payers.
What's the endgame? AQ's platform pairs engineered bacteriophages with a colour-changing dye that shifts when the virus binds to disease markers in urine. Results read on a standard plate reader or through the company's AQ MOBI smartphone app. AQ pitches this as a cheaper, more stable alternative to antibody-based assays.
The expansion: A Hong Kong holding company, AQ Biotech GlobalDealroom has a profile for this one. Try Dealroom →, oversees two mainland joint ventures formed this spring. AQ Biotech Nanjing, set up May 8 with OG PharmaceuticalsDealroom has a profile for this one. Try Dealroom →, targets prostate and urological cancers; AQ Biotech ChengduDealroom has a profile for this one. Try Dealroom →, formed May 14 with Sichuan Yiaijinxuan TechnologyDealroom has a profile for this one. Try Dealroom →, pursues Parkinson's disease screening. The Nanjing venture works with Jiangsu Cancer Hospital, the Chengdu venture with West China Hospital of Sichuan University.
The hire: AQ added Dongqing Wei, an artificial intelligence for life sciences professor at Shanghai Jiao Tong University, to its board as senior advisor in May. The move strengthens its scientific bench as it scales clinical work across Chinese hospitals.
What could go wrong? Research teams in Nanjing and Shanghai have measured 737 urine samples, accumulating over 120,000 data points. Whether that volume translates to clinical validation at the scale regulators require remains an open question.
The signal: At €2.5 million, the round sits in the 91st percentile for seed deals in Finland by size, per an analysis of 1,426 rounds. Small European biotechs increasingly look to China's vast patient pools to build the evidence base commercialisation demands — a bet that clinical scale abroad can offset a limited home market.
Image credit: Generated with Gemini
